NCT05920408 is a Phase 1, PHASE2 clinical trial of EXS21546 in Advanced Solid Tumours, sponsored by Exscientia AI Limited.

Who is sponsoring NCT05920408?

NCT05920408 is sponsored by Exscientia AI Limited.

What drugs are being tested in NCT05920408?

Interventions in NCT05920408: EXS21546.

What condition does NCT05920408 study?

NCT05920408 studies Advanced Solid Tumours.

Is NCT05920408 still recruiting?

NCT05920408 is currently terminated. Last updated 8 November 2023.

Last reviewed 2023-11-08 · How we verify

NCT05920408

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours

Terminated Phase 1, PHASE2 Last updated 8 November 2023

What this trial tests

Phase 1, PHASE2 trial testing EXS21546 in Advanced Solid Tumours in 6 participants. Terminated before completion.

Timeline

11 April 2023

Primary endpoint
27 September 2023

23 October 2023

Quick facts

Lead sponsor	Exscientia AI Limited
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	11 April 2023
Primary completion	27 September 2023
Estimated completion	23 October 2023
Sites	5 locations across Belgium, France

Drugs / interventions tested

EXS21546 — full drug profile →

Conditions studied

Advanced Solid Tumours — all drugs for Advanced Solid Tumours →

Sponsor

Exscientia AI Limited — full company profile →

Who can join

18 and older, any sex, with Advanced Solid Tumours. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A phase 1B/2A study to assess the safety, tolerability, pharmacokinetic and anti-tumoral activity of EXS21546 in combination with a PD-1 inhibitor in patients with advanced solid tumours.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools.
Dewaker V, Morya VK, Kim YH, Park ST, et al · · 2025 · cited 25× · PMID 40155973 · DOI 10.1186/s40364-025-00764-4
The changing scenario of drug discovery using AI to deep learning: Recent advancement, success stories, collaborations, and challenges.
Chakraborty C, Bhattacharya M, Lee SS, Wen ZH, et al · · 2024 · cited 25× · PMID 39257717 · DOI 10.1016/j.omtn.2024.102295
Orphan peptide and G protein-coupled receptor signalling in alcohol use disorder.
Anversa RG, Maddern XJ, Lawrence AJ, Walker LC. · · 2024 · cited 4× · PMID 38073127 · DOI 10.1111/bph.16301

Verify or expand the search:

Other recruiting trials for Advanced Solid Tumours

Currently open trials in the same condition.

NCT06868199 — A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
NCT06795412 — Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06815575 — A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours. · Phase 1 · recruiting
NCT05701527 — A Study of EBC-129 in Advanced Solid Tumours · Phase 1 · recruiting
NCT06927349 — A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Solid Tumors. · Phase 1 · recruiting

Other Exscientia AI Limited trials

Trials by the same sponsor.

NCT06648512 — Association of Ex Vivo Drug Response ( EVDR) and Clinical Outcome in Acute Myeloid Leukaemia (EXCYTE-2) · completed
NCT06068738 — Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer · terminated
NCT04727138 — 3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546 · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05920408 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Exscientia AI Limited
Last refreshed: 8 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05920408.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing